Study #2021-1107
A Phase 1, Open-label Study to Assess the Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered (14C)-SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemia
MD Anderson Study Status
Not Accepting
Treatment Agent
Revumenib
Description
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Leukemia
Study phase:
Phase I
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.